LEROCHOL®

(lerodalcibep-liga) Injection 300 mg/1.2 mL

For adults with hypercholesterolemia, including those with HeFH

Help get your patients' LDL-C down to their target and keep it there with LEROCHOL

A third-generation PCSK9 inhibitor designed to support long-term treatment[1,2]

Robust, sustained LDL-C lowering up to 60%[1-3,*]

A once-monthly, self-administered, subcutaneous injection[2]

Extended room temperature storage for up to 3 months[2,†]

HeFH, heterozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9 inhibitor.

*Indicated as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including HeFH.[2]

†Store refrigerated at 2°C to 8°C (36°F to 46°F). LEROCHOL may be kept at room temperature up to 25°C (77°F) in the original carton and must be used within 3 months of being removed from the refrigerator. If not used within 3 months, discard LEROCHOL.[2]

See next page for information on the Cash-Pay Program for LEROCHOL.

IMPORTANT SAFETY INFORMATION

Adverse Reactions

- The most commonly occurring adverse reactions in clinical trials in primary hyperlipidemia in adults (including heterozygous familial hypercholesterolemia [HeFH]) ≥2% of patients treated with LEROCHOL® (lerodalcibep-liga) and occurring more frequently than with placebo were nasopharyngitis (15% and 14% versus placebo), local injection site reactions (12% and 5% versus placebo) and peripheral edema (2% and <1% versus placebo).

Please see additional Important Safety Information on the next page and full Prescribing Information at LEROCHOL.com.

LEROCHOL®
(lerodalcibep-liga) Injection 300 mg/1.2 mL

How to get LEROCHOL

$199

Cash-Pay Program‡

Follow these steps to ensure your cash-paying patients get LEROCHOL for $199:

1. Enter prescription in EMR and select HealthDyne Pharmacy for home-delivery fulfillment

NPI: 1093974982 | NCPDP eScribe: 1035371

2. Instruct patient to expect a text from 833-772-4142, which is HealthDyne reaching out with instructions to register on the patient portal, where they will:

- Create an account
- Provide prescription information, including their known allergies
- Submit a payment method

REMIND YOUR PATIENT TO COMPLETE ALL NECESSARY INFORMATION ON THE HEALTHDYNE PORTAL TO AVOID ANY DELAYS.

Questions for HealthDyne Pharmacy? Please call 866-778-6350

If your patient prefers to submit through their insurance, prescription must still be submitted through HealthDyne Pharmacy for fulfillment. Please note, some insurance companies may not cover at this time.

‡LEROCHOL prescriptions filled by HealthDyne Pharmacy, the licensed pharmacy provider. Terms and conditions apply. Visit LEROCHOL.com.

See next page for information on dosing & administration support.

IMPORTANT SAFETY INFORMATION (*cont'd*)

Adverse Reactions (*cont'd*)

- The most commonly occurring adverse reactions in clinical trials in HeFH (≥2% of patients treated with LEROCHOL and occurring more frequently than with placebo) were injection site reactions (18% and 3% versus placebo), nasopharyngitis (13% and 9% versus placebo), diarrhea (3% and 1% versus placebo), nausea (2% and 0% versus placebo) and peripheral edema (2% and <1% versus placebo).

Please see additional Important Safety Information on the next page and full Prescribing Information at LEROCHOL.com.

LEROCHOL®
(lerodalcibep-liga) Injection 300 mg/1.2 mL

Dosing & Administration

- Each LEROCHOL prefilled syringe is packaged individually[2]
- LEROCHOL is a convenient, single, subcutaneous injection taken once a month via self-administration[2]
- LEROCHOL can be stored at room temperature for up to 3 months[2,*]

Patients may need guidance taking their monthly dose. Scan the QR code to access the Instructions for Use Reference Guide.

See previous page for information on the Cash-Pay Program for LEROCHOL.

*Store refrigerated at 2°C to 8°C (36°F to 46°F). LEROCHOL may be kept at room temperature up to 25°C (77°F) in the original carton and must be used within 3 months of being removed from the refrigerator. If not used within 3 months, discard LEROCHOL.[2]

IMPORTANT SAFETY INFORMATION *(cont'd)*

Adverse Reactions *(cont'd)*

- The most frequent adverse reaction leading to treatment discontinuation in trials in primary hypercholesterolemia in adults was injection site reactions, with a higher frequency in the LEROCHOL® treated group compared to placebo-treated patients (1% versus 0%).

Immunogenicity

- LEROCHOL is a recombinant fusion protein. As with all therapeutic proteins, there is potential for immunogenicity with LEROCHOL.

INDICATIONS

LEROCHOL® (lerodalcibep-liga) is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

Please see full Prescribing Information at LEROCHOL.com.

References: 1. LEROCHOL [prescribing information]. LIB Therapeutics; 2025. **2.** Kereiakes D, Fourie N, Engelbrecht J, et al. Long term efficacy and safety of lerodalcibep in patients with atherosclerotic cardiovascular disease (LIBerate-CVD). *Atherosclerosis*. 2024;395:118465. **3.** Klug EQ, Llerena S, Burgess LJ, et al. Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial. *JAMA Cardiol*. 2024;9(9):800-807.

LIB THERAPEUTICS

© 2026 LIB Therapeutics, Inc. All Rights Reserved. PRO-1011-v2 07/26